Compounds 6 and 9 possessed activity comparable to fluconazole against C. albicans with a minimum inhibitory concentration of 12.5 m g/mL.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Some benzimidazole derivatives were synthesized and their in vitro antifungal activities were tested against Candida albicans, Candida glabrata and Candida krusei.
📊
Key Findings & Data:Some benzimidazole derivatives were synthesized and their in vitro antifungal activities were tested against Candida albicans, Candida glabrata and Candida krusei.
💡
Conclusion & Impact:Compounds 6 and 9 possessed activity comparable to fluconazole against C. albicans with a minimum inhibitory concentration of 12.5 m g/mL.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Benzimidazole · thiourea · antifungal
Abstract
Some benzimidazole derivatives were synthesized and their in vitro antifungal activities were tested against Candida albicans, Candida glabrata and Candida krusei. Compounds 6 and 9 possessed activity comparable to fluconazole against C. albicans with a minimum inhibitory concentration of 12.5 m g/mL.
Özet
Some benzimidazole derivatives were synthesized and their in vitro antifungal activities were tested against Candida albicans, Candida glabrata and Candida krusei. Compounds 6 and 9 possessed activity comparable to fluconazole against C. albicans with a minimum inhibitory concentration of 12.5 m g/mL.
KILCIGİL, G. A., ALTANLAR, N. (2006). Synthesis and Antifungal Properties of Some Benzimidazole Derivatives. Turkish Journal of Chemistry, Cilt: 30 - Sayı: 2, 223–228. https://ajindex.com/articles/220574
V.L. Khairnar, S.R. Lockhande, M.R. Patel and B.G. Khadse, Chemical Abstract 95, 203833h (1981).
L.L. Kruse, D.L. Ladd, P.B. Harrsch, F.L. McCabe, S.M. Mong, L. Faucette and R. Johnson, J. Med. Chem., 409-417 (1989).
I. Islam, E.B. Skibo, R.T. Dorr and D.S. Alberts, J. Med. Chem. 34, 2954-2961 (1991).
V.J. Habernickel, Drugs made in Germany, 35, 97 (1992).
T. Fukuda, T. Saito, S. Tajima, K. Shimohara and K. Ito, Arzneim.-Forsch./Drug Res. 34, 805-810 (1984).
H. Nakano, T. Inoue, N. Kawasaki, H. Miyataka, H. Matsumoto, T. Taguchi, N. Inagaki, H. Nagai and T. Satoh, Chem. Pharm. Bull. 47, 1573-1578 (1999).
B. Can-Eke, M.O. Puskullu, E. Buyukbingol and M. ˙I¸scan, Chemico-Biological Interactions 113, 65-77 (1998). C. Ku¸s, G. Ayhan-Kılcıgil, B. Can-Eke and M. ˙I¸scan, Arch. Pharm. Res. 27, 156-163 (2004).
G. Ayhan-Kılcıgil, C. Ku¸s, T. C¸ oban, B. Can-Eke and M. ˙I¸scan, Journal of Enzyme Inhibition and Medicinal Chemistry 19, 129-135 (2004). H. G¨oker, G. Ayhan-Kılcıgil, M. Tun¸cbilek, C. Ku¸s, R. Ertan, E. Kendi, S. ¨Ozbey, M. Fort, C. Garcia and A.J. Farre, Heterocycles 51, 2561-2573 (1999).
F.S.G. Soliman, S.M. Rida, E.A.M. Badawey and T. Kappe, Arch. Pharm. 317, 951-958 (1984).
R.A. Coburn, M.T. Clark, R.T. Evans and R.J. Genco, J. Med. Chem. 30, 205-208(1987).
N.S. Habib, S. Abdel-Hamid and M. El-Hawash, Farmaco, 44, 1225-1232 (1989). H. G¨oker, C. Ku¸s, D.W. Boykin, S. Yıldız and N. Altanlar, Bioorg. Med. Chem. 10, 2589-2596 (2002). S. ¨Ozden, H. Karata¸s, S. Yıldız and H. Goker, Arch. Pharm. Pharm. Med. Chem. 337, 556-562 (2004). S. ¨Ozden, D. Atabey, S.Yıldız and H. G¨oker, Bioorg. Med. Chem. 13, 1587-1597 (2005). I. K¨u¸c¨ukg¨uzel, G. K¨u¸c¨ukg¨uzel, S. Rollas and M. Kiraz, Bioorg. Med. Chem. Letters 11, 1703-7007 (2001).
M.S. El-Gaby, J.A. Micky, N.M. Taha and M.A.M. El-Sharief, J. Chin. Chem. Soc. 49, 407-414 (2002). C. Ku¸s, H. G¨oker, G. Ayhan, R. Ertan, N. Altanlar and A. Akın, Il Farmaco 51, 413-417 (1996). H. G¨oker, M. Tun¸cbilek, G. Ayhan and N. Altanlar, Il Farmaco 53, 415-420 (1998).
G. Ayhan-Kılcıgil, M. Tun¸cbilek, N. Altanlar and H. G¨oker, Il Farmaco 54, 562-565 (1999).
G. Ayhan-Kılcıgil and N. Altanlar, Il Farmaco 58, 1345-1350 (2003).
H. Willitzer, D. Brauniger, D. Engelmann, D. Krebs, W. Ozegowski and M. Tonew, Pharmazie 33, 30-38 (1978).